

LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K

April 22, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

April 22, 2002

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Summary information of the Company dated April 22, 2002.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By /s/ BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President
and Secretary

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

Date: April 22, 2002

This information contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2001 and subsequent filings.

How Laboratory Testing Works

Laboratory Testing is the "Gateway to Quality Health Care":

- 1) Patient visits doctor;
- 2) Doctor orders laboratory tests with diagnosis information;
- 3) Doctor or patient service center (PSC) draws sample;
- 4) Laboratory performs tests;
- 5) Test results reported to doctor;
- 6) Doctor makes diagnosis and treatment begins

The Clinical Laboratory Testing Market
US market is approximately \$34-36 billion

CLINICAL LABORATORY TESTING		INDEPENDENT CLINICAL LABORATORIES	
Hospitals	49%	All others	84%
Independent Clinical Labs	39%	LabCorp(\$2.2b)	16%
Physician Offices	12%		

Source: Company estimates, industry reports & 2001YE revenue for LabCorp

Profile of LabCorp

- Nationwide network of 24 primary testing locations and 900 patient service centers
- Conducts tests on 280,000 specimens daily
- Offers more than 4,000 test procedures
- Serves over 200,000 physicians and other health care providers
- More than 19,000 employees nationwide

MAP OF LABCORP'S PRIMARY TESTING LOCATIONS & PSC'S

2002 Strategic Goals

- Maintain national coverage for all key customers
- Expand upon leading position in genomic testing
- Evaluate appropriate acquisition candidates

GENOMIC STRATEGY

UTILIZE DNA TESTING LEADERSHIP TO EXECUTE GENOMIC LEADERSHIP STRATEGY

- Targeted introduction of new tests

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

- Acquire innovative technology
- License/Partner to expand menu

GENOMIC STRATEGY UPDATE

INTERNAL	ACQUISITION	LICENSE/PARTNER
CMBP: - Cancer - Genetics (Cystic Fibrosis) - Infectious Disease (GENOSURE)	NGI: - Infectious Disease Hepatitis C - Cancer: Melanoma Breast	MYRIAD GENETICS: Predictive tests: - Breast/Ovarian and Colon Cancer - Melanoma - Hypertension
CLINICAL TRIALS: - Drug metabolism	VIROMED: - Infectious Disease HIV Hepatitis - Real-time PCR	EXACT SCIENCES: - Colorectal Cancer
POSITITIVE OUTCOMES: (being tested)	CENTER FOR GENETIC SERVICES: - Expanded Genetics Capabilities in Southwest	ALPHA: - PCR Plasma VIROLOGICS: - HIV Phenotyping VIRCO: - HIV Phenotyping

Financial Performance

Price & Volumes: Trends by Payor Type

	2000		2001		YTD MAR 2002	
	PPA	Accessions	PPA	Accessions	PPA	Accessions
	\$	millions	\$	millions	\$	millions
Client (Physicians)	22.70	27.1	24.46	27.9	25.16	7.0
Patient	102.87	2.2	111.28	2.5	115.73	0.6
Third Party (MC/MD/Insurance)	29.80	10.3	31.59	12.2	32.48	3.3
Managed Care						
- Capitated	8.89	10.6	8.90	11.9	9.52	3.1
- Fee for service	42.32	16.0	43.45	17.2	44.53	4.7
Total	28.97	26.6	29.27	29.1	30.59	7.8
LabCorp Total	\$28.98	66.2	\$30.69	71.7	\$31.50	18.7

Financial Performance

Revenue Analysis by Business Area

	YTD MAR 2001			
	Revenue \$Million	Accns 000	%Accns to total	PPA \$
Prior Genomic	39.7	330.0	1.9%	120.38

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

Add'l Genomic*	25.9	623.8	3.6%	41.60
Other Esoteric	50.3	1,295.5	7.5%	38.80
-----	-----	-----	-----	-----
All Esoteric:	115.9	2,249.3	13.0%	51.55
-----	-----	-----	-----	-----
Core:				
-----	409.5	15,069.0	87.0%	27.17
Total:	525.4	17,318.3	100.0%	30.34
-----	-----	-----	-----	-----

	YTD MAR 2002				02 vs 01
	Revenue	Accns	%Accns	PPA	PPA
	\$Million	000	to total	\$	Incr/ (Decr)
	-----	-----	-----	-----	-----
Prior Genomic	46.3	404.8	2.2%	114.34	(5.0)%
Add'l Genomic*	30.9	768.8	4.1%	40.24	(3.3)%
Other Esoteric	57.5	1,379.6	7.3%	41.65	7.3%
-----	-----	-----	-----	-----	-----
All Esoteric:	134.7	2,553.2	13.6%	52.75	2.3%
-----	-----	-----	-----	-----	-----
Core:	455.3	16,181.0	86.4%	28.14	3.6%
-----	-----	-----	-----	-----	-----
Total:	590.0	18,734.2	100.0%	31.50	3.8%
-----	-----	-----	-----	-----	-----

* Includes identity testing and gene probes (chlamydia and gonorrhea)

First Quarter Operating Results (\$ in millions)

	3/31/01	3/31/02
	-----	-----
Revenue	525.4	590.0
Operating Expense	438.1	473.6
	-----	-----
Operating Income	87.3	116.4
	=====	=====
Margin	16.6%	19.7%
EBITDA	110.3	137.6
	=====	=====
Margin	21.0%	23.3%
Bad Debt % to revenue	9.70%	8.75%
DSO	67	60

2002 First Quarter Financial Achievements

- Increased revenues per day 14.0% (volume 10%; price 4%)
- Increased operating income 33%
- Increased EBITDA 25%
- Increased diluted EPS 33%
- Increased operating cash flow 74%

Recent Accomplishments

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

- Expanded Aetna Agreement in CT, NJ, and NY (including NYC)
- New genomics tests for hepatitis B and C
- Successful offering of Roche-owned shares
- Replaced \$450 million revolver with new \$300 million credit facility
- Announced two-for-one stock split

Quarterly DSO Trend

DSO Trend December '97 through March '02

December 1997	- 79 days	June 2000	- 70 days
December 1998	- 83 days	September 2000	- 70 days
March 1999	- 83 days	December 2000	- 68 days
June 1999	- 79 days	March 2001	- 67 days
September 1999	- 76 days	June 2001	- 64 days
December 1999	- 74 days	September 2001	- 62 days
March 2000	- 72 days	December 2001	- 58 days
		March 2002	60 days

Financial Guidance for 2002

- Increase overall revenues by approximately 12% compared to 2001 (8-9% volume; 3-4% price)
- EBITDA margins of approximately 23% of sales
- EPS growth of approximately 30% under new accounting rules for 2001
- Bad debt rate of 8.75% of sales
- Capital expenditures of approximately \$85 million
- Net interest expense of \$12 million
- A tax rate of approximately 41.5%

Growth Opportunities

Revenue

- New Tests - Cystic Fibrosis, hepatitis B and C, HPV, etc.
- Conversion to Monolayer Paps
- New Licenses/Partnerships - Myriad Genetics, EXACT Sciences, etc.
- Ongoing Acquisition Strategy
- Genomic Strategy/Mix Shift Leverage
- Improving Regulatory/Reimbursement Environment

Profit Improvement Opportunities

Cost Structure

- Bad Debt Reduction
- Further Operational Consolidation
- Technology Improvements - Higher Throughput and Efficiencies

Value Drivers

Labcorp:

- Proven strategy for growth
- Pioneer in identifying and commercializing innovative technologies
- National infrastructure connects large scale proficiency with wide scale technological expertise
- Strong balance sheet

Industry:

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

- New advances in scientific research will generate growth and demand for molecular testing
- Aging population

Other Financial Information

March 31, 2002

(\$ in millions, except per share amounts)

	Q1 02

Depreciation	\$ 16.1
Amortization	\$ 5.1
Capital expenditures	\$ 18.4
Cash flows from operations	\$112.2
Bad debt as a percentage of sales	8.75%
Effective interest rate on debt	2.00%
Days sales outstanding	60